Media coverage about Horizon Therapeutics (NASDAQ:HPTX) has been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Horizon Therapeutics earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.1798212443872 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
NASDAQ HPTX opened at $45.99 on Friday. Horizon Therapeutics has a 1 year low of $20.23 and a 1 year high of $46.96.
About Horizon Therapeutics
Horizon Therapeutics, Inc, formerly Hyperion Therapeutics, Inc, is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder.
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.